Loading…
Makes an ultra-sensitive proteomics platform (NULISA) that detects trace protein biomarkers for research and diagnostics.
Makes an ultra-sensitive proteomics platform (NULISA) that detects trace protein biomarkers for research and diagnostics.
Sells instruments and then earns repeatedly on the assay kits used on them, so reagent sales follow the number of samples customers run. Customers are mostly research labs, so research-grant funding affects demand.
Moat: narrow (IP / patents, process know-how). Proprietary ultra-sensitive protein detection technology differentiated from standard immunoassays.
Headquarters: Fremont, California, US · Founded: 2018 · Employees: 222
Size Alamar Biosciences (ALMR) is a United States Health Care company (Biotechnology) with a market value of $1.95B, the 1812th largest of 3,117 United States companies the cockpit tracks. Shares closed at $28.05 on 6 Nov 2026.
Performance Over six months the shares gained 17.1%, against +22.9% for the median peer and -1.1% for the United States market (cap-weighted) — 9th lowest of 20 in its peer set.
Growth Revenue grew 195.2% over the last twelve months (peer median +10.8%); the operating margin is -42.2% (peer median -8.8%).
Valuation It trades at 23.6× enterprise value to sales against a peer median of 8.9× (4th most expensive of 15).
Capital Return on invested capital runs 28.0 points below its cost of capital (6.3% WACC).
Short interest Short interest is 3.9% of the free float (15 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | n/a | $74.2M | $25.1M |
| Revenue growth | — | +195% | — |
| Gross profit | n/a | $41.7M | $8.61M |
| EBITDA | n/a | -$27.5M | -$46.4M |
| Net income | n/a | -$29.8M | -$47.1M |
| Free cash flow | n/a | -$59.0M | -$58.2M |
| Capital expenditure | n/a | $6.38M | $3.39M |
| Total debt | $51.4M | $276M | $268M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Alamar Biosciences ALMR | $1.95B | +17% | +195% | -42% | 23.6× | n/a |
| Thermo Fisher Scientific TMO | $257B | +50% | +8% | 19% | 6.2× | 20.9% |
| Standard BioTools LAB | n/a | -38% | n/a | n/a | n/a | n/a |
| Bio-Techne TECH | $11.4B | +51% | 0% | 22% | 9.4× | 31.3% |
| Nautilus Biotechnolgy NAUT | n/a | -17% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ALMR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.3% | +4.3% | 8th highest of 20 |
| 6-month return | +17.1% | +22.9% | 9th lowest of 20 |
| Distance from 52-week high | -29.2% | -26.1% | 8th lowest of 20 |
| Revenue growth (TTM) | +195.2% | +10.8% | 4th highest of 17 |
| Operating margin | -42.2% | -8.8% | 7th lowest of 17 |
| EV / Sales | 23.6× | 8.9× | 4th most expensive of 15 |
| ROIC minus cost of capital | -28.0 pp | -6.4 pp | 2nd lowest of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Alamar Biosciences ALMR | United States | $1.95B | +17% | +195% | -42% | 23.6× | n/a | n/a |
| Maravai Lifesciences MRVI | United States | $1.95B | +108% | -3% | -13% | 9.3× | n/a | n/a |
| BioCryst Pharmaceuticals BCRX | United States | $1.97B | -11% | +60% | 42% | 2.5× | -10.6% | +117.9% |
| Alvotech ALVO | United States | $1.90B | +49% | -12% | 9% | 6.5× | n/a | n/a |
| GemPharmatech 688046.SS | China | $2.01B | +59% | +25% | 22% | 13.3× | 35.7% | +24.8% |
| First Tracks Biotherapeutics TRAX | United States | $2.01B | +145% | n/a | n/a | n/a | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $2.04B | -1% | n/a | n/a | n/a | n/a | n/a |
| Replimune REPL | United States | $2.05B | +547% | n/a | n/a | n/a | n/a | n/a |
| Zenas BioPharma ZBIO | United States | $1.84B | +44% | -93% | -27,390% | 1,588.4× | n/a | n/a |
| Vir Biotechnology VIR | United States | $2.07B | +34% | +1,496% | -92% | 5.4× | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.83B | 0% | +556% | -43% | 15.2× | n/a | n/a |
| Shenzhen Kangtai Biological Products 300601.SZ | China | $2.11B | -9% | -9% | 6% | 5.6× | 25.3% | +3.4% |
| Hitgen 688222.SS | China | $2.12B | +23% | +42% | 27% | 19.1× | 38.7% | +16.8% |
| Novavax NVAX | United States | $1.78B | +7% | -62% | -29% | 3.3× | n/a | n/a |
| Vera Therapeutics VERA | United States | $2.15B | -18% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Hengtong 600226.SS | China | $1.76B | -23% | +71% | 0% | 4.5× | n/a | n/a |
| Lycia Therapeutics LYCA | United States | $1.76B | n/a | -55% | -593% | n/a | n/a | n/a |
| Absci ABSI | United States | $1.75B | +72% | -62% | -8,411% | 991.7× | n/a | n/a |
| Stoke Therapeutics STOK | United States | $1.74B | -19% | -86% | -913% | 50.3× | n/a | n/a |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.19B | +25% | +259% | 60% | n/a | n/a | n/a |
| CanSino Biologics 688185.SS | China | $1.73B | +21% | +30% | -4% | 8.5× | n/a | n/a |